OLR1 and cancer: And for the 100 GC patients, the OS of patients with high LOX-1 expression was significantly shorter than those with low LOX-1 expression in both early-stage cancer (P = 0.046; Supplementary Fig. S2a) and advanced-stage cancer (P < 0.001; Supplementary Fig. S2b).